Harvard Bioscience(US:HBIO)2026-03-12 13:00Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $23.7 million, above the midpoint of guidance but down from $24.6 million in Q4 2024 [12] - Gross margin improved to 59.77%, up 260 basis points from 57.1% in Q4 2024, marking the highest gross margin in the last seven quarters [12][13] - Adjusted EBITDA for Q4 2025 was $3.8 million, reflecting a 27% year-over-year growth [6][13] - Full year revenue for 2025 was $86.6 million, down from $94.1 million in 2024, primarily due to tariffs and delayed NIH funding [14] - Full year adjusted EBITDA increased 12.5% to $8.1 million from $7.2 million in 2024 [15] Business Line Data and Key Metrics Changes - The Americas saw a 2% year-over-year decline in Q4 revenue, driven by lower pharma and academic sales [16] - European revenues decreased by 12% year-over-year in Q4, attributed to lower academic sales [17] - In China and the Asia Pacific, Q4 revenues increased by 10% year-over-year, supported by growth in preclinical distribution [17] Market Data and Key Metrics Changes - NIH revenue constitutes about 20% of U.S. revenue, with expectations for improvement in orders following recent approvals [27] - The company experienced a backlog at the highest level in over two years, indicating positive demand trends [36] Company Strategy and Development Direction - The company is transitioning from a traditional life science tools provider to a leader in translational science, focusing on bridging in vivo and in vitro research [8] - Key strategic priorities include leading the translational science bridge, accelerating high-margin innovation, expanding consumables and recurring revenue, and maintaining operational excellence [9][10] - The company aims for low single-digit revenue growth and high single-digit Adjusted EBITDA growth in 2026, driven by higher margin new product innovations [10][22] Management Comments on Operating Environment and Future Outlook - The life science industry is undergoing a fundamental shift, with drug development remaining inefficient [7] - The company is well-positioned to manage volatility due to its diversified geographic footprint and improved cost structure [10] - 2025 was characterized as a strategic reset, with 2026 expected to be a year of growth in both top and bottom lines [10][23] Other Important Information - The company completed a comprehensive refinancing that extended debt maturity to 2029 and reduced annual debt service by $3 million [4][19] - The company has reinstated bonuses and merit-based compensation for employees in 2026, which had been suspended in 2025 [21] Q&A Session Summary Question: How quickly do you think NIH approval will improve the academic environment? - Management expects to see a positive impact towards the end of Q1 and into Q2 following NIH approval [26][27] Question: What is the expected growth for key products like BTX and Mesh MEA in 2026? - Both products are expected to grow in double digits this year [28] Question: What are the expectations for the Asia Pacific revenue turnaround? - Management noted improvement in orders and expects a return to normal cadence in Asia, barring any new tariff issues [35] Question: How is the pharmaceutical biotech CRO side of the business performing? - The pharma and biotech segment is up year-to-date, and management expects this trend to continue [39]